IDH1 and central nervous system cancer: Within the IDH1 mutation cohort, nine cases (18.8%) had high-grade glioma (HGG) lesions, comprising seven cases (14.6%) of glioblastoma, one case (2.1%) of anaplastic astrocytoma, and one case (2.1%) of anaplastic oligodendroglioma.